Pages that link to "Q38073875"
Jump to navigation
Jump to search
The following pages link to The role of fibrate treatment in dyslipidemia: an overview (Q38073875):
Displaying 28 items.
- Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome (Q26801281) (← links)
- P2Y13 receptor regulates HDL metabolism and atherosclerosis in vivo (Q35158162) (← links)
- Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate (Q35894747) (← links)
- The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat. (Q37304485) (← links)
- Critical review of non-statin treatments for dyslipoproteinemia. (Q38186099) (← links)
- Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease (Q38188874) (← links)
- Dyslipidaemia and the military patient (Q38561477) (← links)
- Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options (Q38631018) (← links)
- PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. (Q38674742) (← links)
- An update on PPAR activation by cannabinoids. (Q38808034) (← links)
- Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention (Q39004398) (← links)
- Chalcone Derivatives: Promising Starting Points for Drug Design. (Q39027317) (← links)
- Evaluating bempedoic acid for the treatment of hyperlipidaemia (Q39074339) (← links)
- The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases. (Q39185669) (← links)
- Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. (Q39399592) (← links)
- Cardiovascular disease prevention strategies for type 2 diabetes mellitus (Q39420208) (← links)
- Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport (Q41975402) (← links)
- Cytotoxic effect of a family of peroxisome proliferator-activated receptor antagonists in colorectal and pancreatic cancer cell lines. (Q43974650) (← links)
- Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study (Q45895181) (← links)
- Management of Statin Intolerance in 2018: Still More Questions Than Answers (Q48274059) (← links)
- Pharmacological Intervention to Modulate HDL: What Do We Target? (Q49554117) (← links)
- Dyslipidaemia in the elderly: to treat or not to treat? (Q50180407) (← links)
- Emerging approaches for the treatment of hypertriglyceridemia. (Q51334679) (← links)
- Changes in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease (Q59135837) (← links)
- Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials (Q59796327) (← links)
- Lipid-lowering effects of oleanolic acid in hyperlipidemic patients (Q88963845) (← links)
- The Diagnosis and Treatment of Hypertriglyceridemia (Q92333057) (← links)
- Development of Fibrates as Important Scaffolds in Medicinal Chemistry (Q92918241) (← links)